- Products
Products
Founded in 2004, DIURNAL®, a NEUROCRINE BIOSCIENCES® Company, is a European, UK-headquartered specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency.
- Clinical Resources
Clinical Resources
Diurnal is dedicated to developing new treatments to aid lifelong treatment for rare and chronic endocrine conditions
- R&D
R&D
Our expertise and innovative research activities focus on circadian-based endocrinology (mimicking the body's natural hormone levels) to develop products for rare and chronic endocrine conditions
- Transparency
Transparency
Diurnal is committed to transparency in its interactions. Diurnal commits to following the Association of British Pharmaceutical Industry (ABPI) Code of Practice which has clear requirements for transparency.
- Careers
Careers
Diurnal is a rapidly growing global specialty pharmaceutical company with a highly integrated and very committed team. We're always looking for talented individuals who share our vision. Visit this section to view our current opportunities.
- Awards
Awards
A limited number of awards is available each year, and all applications will be judged objectively by an independent panel.
Click here to view the UK GB/NI Prescribing Information
Efmody® (hydrocortisone modified-release hard capsules), development name Chronocort® is Diurnal’s second, commercialised medicine and is indicated as a treatment for adult and adolescent patients (12 years and older) with the rare condition congenital adrenal hyperplasia (CAH)¹. Efmody was approved by the European Commission in May 2021 for the European Economic Area (including Northern Ireland)(EEA) and by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) in July 2021 for Great Britain (England, Wales and Scotland).
Efmody® is a preparation of hydrocortisone that has been specifically designed to mimic the circadian rhythm of cortisol, when given in a twice-a-day “toothbrush” regimen, (administered last thing at night before sleep and first thing in the morning on waking) to control androgen excess and chronic fatigue in patients with diseases of cortisol deficiency. It is a multi-particulate formulation presented as a capsule and is available in doses of 5mg and 10mg.
